FDA Adverse Event Malfunction Summary report: N

TELIGEN

MDR report key: 3210367 · Received July 8, 2013

Report

Report Number
2124215-2013-08829
Event Type
Malfunction
Date Received
July 8, 2013
Date of Event
April 17, 2013
Report Date
July 23, 2018
Manufacturer
GUIDANT CRM CLONMEL IRELAND
Product Code
LWP
PMA / PMN Number
P010012
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Additional Manufacturer Narrative · 1

THE LOCAL AREA FIELD REPRESENTATIVE WAS CONTACTED FOR ADDITIONAL INFORMATION. AT THIS TIME, NO FURTHER INFORMATION IS AVAILABLE. AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Description of Event or Problem · 1

BOSTON SCIENTIFIC RECEIVED INFORMATION VIA THE PATIENT'S HOME REMOTE MONITORING SYSTEM THAT THIS RIGHT VENTRICULAR (RV) LEAD AND DEVICE DISPLAYED HIGH, OUT OF RANGE SHOCK IMPEDANCE MEASUREMENTS. THE LOCAL BOSTON SCIENTIFIC FIELD REPRESENTATIVE HAD NOT BEEN CONTACTED BY THE PATIENT'S CLINIC REGARDING ANY FOLLOW UP. THERE WERE NO ADVERSE PATIENT EFFECTS. THE SYSTEM REMAINS IN SERVICE.

Description of Event or Problem · 1

ADDITIONAL INFORMATION WAS RECEIVED THAT ANOTHER ALERT WAS RECEIVED FOR OUT-OF-RANGE SHOCK IMPEDANCE ON THE RV LEAD. BOSTON SCIENTIFIC TECHNICAL SERVICES (TS) REVIEWED THE DEVICE DATA AND FOUND THAT THE SHOCK IMPEDANCE HAD BEEN STABLE AT ABOUT 100-110 OHMS OVER THE PAST YEAR. TS RECOMMENDED CONTINUED MONITORING AND POTENTIALLY BRINGING THE PATIENT IN FOR COMMANDED SHOCK TESTING. THIS PRODUCT REMAINS IN SERVICE. NO ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
309729 TELIGEN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR LWP GUIDANT CRM CLONMEL IRELAND E102

Patients

Seq Age Sex Outcome Treatment
1 51 YR E102| 0180